4th International Meeting on Aortic Diseases

New insights into an old problem

CHU Liège, APF

September 11-13, 2014

Crowne Plaza Hotel
Liège, Belgium

www.chuliege-imaa.be
It is a great pleasure for me to welcome you to the fourth edition of the International Meeting on Aortic Diseases in this new venue. IMAD 2014 is focusing on basic research, genetic aspects of aortic aneurysms, aortic dissections, aortitis, and their treatment as well as on the new pathophysiological concepts in bicuspid aortic valve, TAVI and surgical treatment of aortic valve diseases. We have also organized a parallel perfusion session to provide information about the latest innovation in perfusion.

This year again, the industry supporters will organize hand-on workshops and symposia. You will find the full program on page 16. Furthermore, young investigators will present many interesting papers in the platform and poster sessions. ePoster presentations have been scheduled for Saturday morning. Saturday afternoon, the four best studies will be awarded by the Aneurysmal Pathology Foundation (APF).

On Friday evening, please join us in a convivial atmosphere for the Official dinner in the beautiful Palais Provincial (only a 5 min. walk from the Crowne Plaza). I truly hope you will have a great time in Liège and enjoy the 4th International Meeting on Aortic Diseases!

Natzi Sakalihasan

Under the patronage of:

- University of Liège
- Cardiovascular Surgery Department of CHU of Liège
- Province of Liège
- APF (Aneurysmal Pathology Foundation)
- Faculty of Medicine, ULg
### Thursday September 11

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.30</td>
<td>Pathogenesis of AAA</td>
</tr>
<tr>
<td>10.00</td>
<td>Coffee break</td>
</tr>
<tr>
<td>10.30</td>
<td>Genetics of AAA</td>
</tr>
<tr>
<td>13.00</td>
<td>Lunch break</td>
</tr>
<tr>
<td>14.00</td>
<td>Epidemiology of AAA</td>
</tr>
<tr>
<td>16.10</td>
<td>Coffee break</td>
</tr>
<tr>
<td>16.40</td>
<td>Recent advances and future directions of AAA</td>
</tr>
<tr>
<td>19.10</td>
<td>End of the sessions</td>
</tr>
</tbody>
</table>

### Friday September 12

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.30</td>
<td>Clinical management and treatment of thoraco-abdominal and abdominal aortic diseases</td>
</tr>
<tr>
<td>10.00</td>
<td>Coffee break</td>
</tr>
<tr>
<td>10.30</td>
<td>Management of aortitis and mycotic aneurysms</td>
</tr>
<tr>
<td>11.30</td>
<td>Industry sponsored symposium</td>
</tr>
<tr>
<td>12.30</td>
<td>Lunch break</td>
</tr>
<tr>
<td>13.30</td>
<td>Challenging cases in aortic pathology</td>
</tr>
<tr>
<td>14.00</td>
<td>Industry sponsored symposium</td>
</tr>
<tr>
<td>15.45</td>
<td>Coffee break</td>
</tr>
<tr>
<td>16.15</td>
<td>Aortic root and thoracic aortic aneurysms</td>
</tr>
<tr>
<td>18.40</td>
<td>End of the sessions</td>
</tr>
</tbody>
</table>

### Saturday September 13

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.30</td>
<td>The treatment of type B dissection</td>
</tr>
<tr>
<td>10.00</td>
<td>Coffee break</td>
</tr>
<tr>
<td>10.30</td>
<td>Genetics and pathology of bicuspid aortic valves</td>
</tr>
<tr>
<td>11.30</td>
<td>Controversies in clinical management of bicuspid aortic valve disease</td>
</tr>
<tr>
<td>13.15</td>
<td>Lunch break</td>
</tr>
<tr>
<td>14.00</td>
<td>Industry sponsored symposium</td>
</tr>
<tr>
<td>15.00</td>
<td>Management of aortic valves: conventional surgery and TAVI</td>
</tr>
<tr>
<td>17.20</td>
<td>Closing remarks &amp; Awards ceremony</td>
</tr>
<tr>
<td>17.50</td>
<td>Adjournment</td>
</tr>
</tbody>
</table>

### Saturday September 13 (Parallel session - Level 2)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>10.00</td>
<td>Innovation in perfusion - Coagulation management</td>
</tr>
<tr>
<td>10.30</td>
<td>Genetics and pathology of bicuspid aortic valves</td>
</tr>
<tr>
<td>10.45</td>
<td>Controversies in clinical management of bicuspid aortic valve disease</td>
</tr>
<tr>
<td>13.15</td>
<td>Lunch break</td>
</tr>
<tr>
<td>15.00</td>
<td>Management of aortic valves: conventional surgery and TAVI</td>
</tr>
</tbody>
</table>

---

**IMAD Official dinner**

Salons du Palais Provincial  
Meeting point at 19.45 in front of the Crowne Plaza (5 min. walk)
Thursday September 11

07.30 Welcoming coffee

08.00 Welcome address, Natzi Sakalihasan

08.15 Distinguished lecture. Aortic aneurysm research: has the holy grail changed? Janet Powell

Pathogenesis of AAA
Gillian Cockerill, Jean-Baptiste Michel

08.30 Do we have to re-invent AAA pathology? Lessons from clinical studies, Jan Lindeman

08.40 Differences in the aneurysm wall could explain gender differences in prevalence rates and rupture risk, Christina Villard

08.50 Elevating plasma HDLs to regress AAA - a therapeutic opportunity? Gillian Cockerill

09.00 Novel mediators involved in oxidative stress and proteolysis in AAA, Jose-Luis Martin Ventura

09.10 Non aortic tissue defects in patients with atherosclerotic AAA, Eric Allaire

09.20 Telomere shortening and oxidative stress in abdominal aortic aneurysm and varicose vein: comparing two dilative vascular pathologies, Domenico Palombo

09.30 Short communications from selected papers
- Role of natural killer cell cytotoxicity pathway in human abdominal aortic aneurysms, Irene Hinterseher
- Transglutaminase 2 – a potential role in aneurysm progression? Kathryn Griffin
- Modulation of abdominal aortic aneurysm vascular smooth muscle cell function by pharmacological inhibition of the native Orai1 Ca2+ channel, Marc Bailey

09.45 Discussion and MCQ

10.00 Coffee break

10.30 Genetics of AAA
Helena Kuivaniemi, Gerard Tromp

10.30 Results from the AAA Meta-GWAS consortium, Gregory Jones

11.00 The Liège AAA family study, Natzi Sakalihasan

11.15 Decision making from gene to intervention for the Marfan syndrome, Yskert Von Kodolitsch

11.30 What’s new in the genetics of thoracic aortic aneurysm? Lut Van Laer

11.45 Short communications from selected papers
- Genetic variants in SEPP1, SELS, TXNRD2, GPX4 and SOD2 are associated with peripheral atherosclerosis and poor left-ventricular function in a comprehensive analysis of polymorphisms in selenoprotein genes in AAA and AIOD, Ewa Strauss

07.30 Age at AAA-diagnosis in siblings to AAA patients, Anneli Linné

Familial vascular Ehlers-Danlos syndrome caused by a mutation in COL5A1, Annette Baas

Diagnostic and prognostic biomarker potential of miR-24 in abdominal aortic aneurysm disease and rupture, Lars Maegdefessel

Circulating microRNA expression signature in PET positive abdominal aortic aneurysms: new potential biomarkers, Audrey Courtois

Genes, molecular mechanisms and risk prediction for abdominal aortic aneurysm, Anne Upma

Reinventing pathophysiology of AAA: dystrophic changes, Stefan Doderer

Pioglitazone competes with EGR1 to suppress PKD1 in Angiotensin II-treated macrophages, Nicoletta Charolidi

Fibrin clot structure in the angiotensin II Murine model of abdominal aortic aneurysm, Katherine Bridge

12.30 Discussion and MCQ

13.00 Lunch break

14.00 Nature vs nurture in AAA pathophysiology, Martin Björck

Five-year outcomes in men screened for AAA – a population-based cohort study, Anders Wanhainen

10-year follow-up of the Western Australia randomized trial of AAA screening, Paul Norman

Characteristics and outcomes of men screened vs not screened for AAA in Sweden, Rebecka Hultgren

14.30 Some last lessons from MASS, Simon Thompson

Risk factors for AAA – insights from a large Swedish cohort study, Martin Björck

Surveillance of small AAA, Simon Thompson

15.00 Discussion

15.20 The rise and fall of AAA, Frank Lederle

15.40 Short communications from selected papers
- Do hernias contribute to increased severity of aneurysmal disease among abdominal aortic aneurysm patients? Mariana Estrelinha

Preliminary data from the Liège Screening programme suggests the reported decline in AAA prevalence is not global, Georgios Makrygiannis
Thursday September 11

- Use of electronic medical records to study abdominal aortic aneurysm: the eMERGE Experience, Gerard Tromp

15.55 Discussion and MCQ

16.10 Coffee break

Recent advances and future directions of AAA
Nicos Labropoulos, Anders Wanhainen

16.40 Hernia and AAA, Jes Lindholt

16.50 Medical treatment for AAA: past and future, Jonathan Golledge

17.00 Results of a randomized trial of open vs endovascular repair for ruptured AAA, Janet Powell

17.10 The RAVI-study and the TicAAA-trial, Anders Wanhainen

17.20 Pathogenesis and management of HIV associated aneurysms, Martin Veller

17.30 Should patients with CAD be screened for aortic aneurysms? Rodolphe Durieux

17.40 Optimal preparation using simulation both in elective and ruptured case, Isabelle Van Herzeel

17.50 Minimizing radiation exposure during endovascular aortic procedures, Nicos Labropoulos

18.00 Can the FEM be used as a predictor for rupture risk in clinical practice? Method and validation so far, Christian Gasser

18.10 Short communications from selected papers
  - Pro-inflammatory role of stem cells in abdominal aortic aneurysms, Evan Ryer
  - Screening of microRNAs expressed in isolated cells of human abdominal aortic aneurysm for the identification of potential biomarkers, Rafaëlle Spear
  - The ectopic adventitial adipocytes of abdominal aortic aneurysm, Hiroki Tanaka
  - The actual bomb in abdominal aortic aneurysm disease ticks... Stephanie Tomee
  - Promising first experience of endovascular treatment of ruptured abdominal aortic aneurysms, Stevo Duvnjak
  - Prevention of incisional hernia after midline laparotomy for abdominal aortic aneurysm treatment: a randomized controlled trial, Olivier Detry

18.50 Discussion and MCQ

19.10 End of the sessions

Friday September 12

08.00 Welcoming coffee

Clinical management and treatment of thoraco-abdominal and abdominal aortic diseases
Tilo Köbel, Eric Verhoeven

08.30 Blunt thoracic and abdominal aortic injury, Benjamin Starnes

08.40 Endovascular repair of chronic thoraco-abdominal dissections with fenestrated endografts, Stéphan Haulon

08.50 New techniques to occlude false-lumen distal back flow in chronic dissections, Tilo Köbel

09.00 Ruptured AAA. Streamlined protocols affect outcome, Benjamin Starnes

09.10 Management of the LSCA in TEVAR, Peter Holt

09.20 Determinants of short-term outcome of EVAR with the use of new generation endograft, Athanassios Giannoukas

09.30 Renal protection during thoraco-abdominal aortic aneurysm repair with Custodiol renal perfusion, Germano Melissano

09.40 Should young patients with AAA receive open surgery and not EVAR? Apostolos Tassiopoulos

09.50 Ruptured aortic aneurysm: experience in Thongnhat hospital, HCMC, Vietnam, Que Do Kim

10.00 Short communication from selected papers
  - Outcomes of persistent intraoperative Type 1a endoleak following standard endovascular aneurysm repair (EVAR), Alistair Millen
  - Functionality and biological response of the Multilayer Flow Modulator Implanted in the abdominal aorta of adult miniature swine, Patricia Kavanagh Edel

10.05 Discussion and MCQ

10.10 Coffee break

Management of aortitis and mycotic aneurysms
Nicos Labropoulos, Martin Veller

10.40 Inflammatory aortic aneurysm: The outcome of endograft stenting for rare miscellaneous aneurysms, Furuzan Numan

10.50 Endovascular treatment of mycotic aortic aneurysms – a European multicenter study, Anders Wanhainen

11.00 Management of Takayasu’s aortitis in 2014, Martin Veller

11.10 TEVAR/EVAR management of aortic fistulas; bronchial, esophageal, enteric, Furuzan Numan

11.20 Discussion and MCQ
Friday September 12

11.30  Industry sponsored symposium (see program p16)

12.30  Lunch break

13.30  Parallel industry workshop (see program p16)

13.30  Challenging cases in aortic pathology
Mario Lachat, Isabelle Van Herzelee, Hence Verhagen

13.30  Treatment of a short neck infrarenal aortic aneurysm (case presentation), Sabrina Houthoofd

13.40  Challenging necks can be treated by EVAR, Hence Verhagen

13.50  Challenging necks can only be treated if the proximal landing zone has been optimized, Benjamin Starnes

14.00  Discussion and MCQ

14.15  (T)EVAR complicated by access problems (case presentation), Sonia Ronchey

14.25  Difficult access remains a contraindication for EVAR, Apostolos Tassiopoulos

14.35  Difficult access can always be overcome, Mario Lachat

14.45  Discussion and MCQ

15.00  Failure of stent-graft at long-term follow-up, Sonia Ronchey

15.10  Endovascular techniques first to treat an increasing aneurysm post-EVAR, Eric Verhoeven

15.20  Conversion is the only solution to avoid rupture in an increasing aneurysm post-EVAR, Germano Melissano

15.30  Discussion and MCQ

15.45  Coffee break

16.15  Aortic root and thoracic aortic aneurysms
Jean-Olivier Defraigne, John Elefteriades

16.25  Complications involving the ascending aorta after TEVAR: incidence and treatment options, Germano Melissano

16.35  Managing the aortic root during pregnancy, Julie De Backer

16.45  Arch aneurysm endovascular repair: global experience with a double branched endograft, Stéphan Haulon

16.55  Practical ascending aneurysm genetics for the surgeon, John Elefteriades

17.05  Discussion

17.15  Ascending aorta: is the endovascular approach realistic? Tilo Köbel

17.25  Redo surgery after type A aortic dissection repair, John Elefteriades

17.35  Fenestrated and branched solutions in the aortic arch: pros and cons of two different endo-techniques, Tilo Köbel

17.45  Retrograde type A in TEVAR, Peter Holt

17.55  Latest (2014) Yale data on appropriate criteria for intervention for the ascending aorta, John Elefteriades

18.05  Short communications from selected papers
- Lessons learned from using the multilayer fluid modulator outside of indications for use in 38 cases, Sherif Sultan
- Report of the French National Registry (N.O.E.) of elective frozen elephant trunk surgery for extensive thoracic aortic disease, Amedeo Anselmi
- Dilation of the ascending aorta: collagen analysis in tissue obtained from patients with bicuspid aortic valve disease compared with tricuspid aortic valve, Salah A. Mohamed
- Bicuspid aortic valve: molecular tissue factors identified prognostic for future aortopathy, Nimrat Grewal

18.25  Discussion and MCQ

18.40  End of the sessions

Social event
IMAD Official dinner

Friday, September 12, 20.00
Salons du Palais Provincial
Meeting point at 19.45 in front of the Crowne Plaza (5 min. walk)
Saturday September 13

08.00 Welcoming coffee
- The treatment of type B dissection
  Jean-Olivier Defraigne, Christoph Nienaber

08.30 Concept of pre-emptive scaffolding in aortic dissection type B, Christoph Nienaber

08.45 Prognostic impact of new information from functional imaging (4d-MRI), Rachel Clough

09.00 Imaging of ongoing inflammation in dissection by PET-CT, Natzi Sakalihasan

09.15 The new criteria of risk in clinically silent type B dissection, Falko Tillwich

09.30 Intensive drug therapy for acute aortic dissection: why we need a randomized trial, Frank Lederle

09.45 Discussion and MCQ

10.00 Coffee break

10.30 ePosters competition (see program p15)

10.30 PARALLEL SESSION (Level 2)
  Jury: Helena Kuivaniemi, Frank Lederle

10.30 Genetics and pathology of bicuspid aortic valves
  Alessandro Della Corte, Bart Loeys

10.30 Comparative biology of progressive dilatation (aneurysm) versus acute infrarapetral rupture (dissection) of the human ascending aorta, Jean-Baptiste Michel

10.45 The molecular basis of bicuspid aortic valve related aneurysmal disease, Bart Loeys

11.00 Novel flow-mediated gene expression signature in patients with bicuspid aortic valve, Per Eriksson

11.00 Aortic dimensions in patients with bicuspid and tricuspid aortic valves, Anders Franco-Cereceda

11.30 Discussion and MCQ

11.30 Controversies in clinical management of bicuspid aortic valve disease
  Alessandro Della Corte, Anders Franco-Cereceda

11.45 Pre-operative and post-operative follow-up of BAV and its complications, Arturo Evangelista

12.00 Imaging flow alterations in BAV aortopathy, Malenka Bissell

12.15 Aortic dissection in BAV patients: the IRAD experience and beyond, Eduardo Bosone

12.30 Controversies in valve surgery for BAV disease, Rita Milewski

12.45 Controversies in surgery for BAV aortopathy, Alessandro Della Corte

13.00 Round-table discussion

13.15 Lunch break

14.00 Industry sponsored symposium (see program p17)

14.00 Management of aortic valves: conventional surgery and TAVI
  Christophe Martinez, Marc Radermecker

15.00 Pre and post TAVI imaging evaluation, Luc Piérard

15.10 Update of the Belgian TAVI registry, Joëlle Kefer

15.20 New technologies in TAVI – Direct aortic-transapical, Robin Heijmen

15.40 Transcatheter aortic valve implantation in patients with ascending aortic dilatation: safety of the procedure and mid-term follow-up, Rita Milewski

15.50 The PROACT trial: valve choice has changed, Marc Gerdisch

16.00 TAVI in intermediate risk surgery: SURTAVI and PARTNER 2 trials, Marc Radermecker

16.10 Alternative endovascular approaches for valve implantation, David Glineur

16.20 Endovascular management of vascular complications, Christophe Martinez

16.30 OnX valve conduit: from table-made to off-the-shelf, a single surgeon experience, Marc Gerdisch

16.40 Short communications from selected papers
  - Aortic complications in bicuspid aortic valve and Marfan syndrome: a histologic comparison, Nimrat Grewal
  - New approach in the treatment of aneurysm of Sinus of Valsalva, Andranik Petrosyan
  - Impact of obesity on the risk of aortic dilatation in patients with bicuspid aortic valve, Marianna Buonocore

17.00 Discussion and MCQ

17.20 Closing remarks & Awards ceremony
  Jean-Olivier Defraigne, Helena Kuivaniemi

17.50 Adjournment
Saturday September 13
PARALLEL SESSION (Level 2 - Salon Grétry)

10.30 Welcome address, Francine Blaffart

I Innovation in perfusion
Francine Blaffart, Gregory Hans

Coagulation management
10.45 Retrospective local results, Jean-Noël Koch
10.55 Alternatives to heparin: dream or reality, Dan Longrois
11.05 Update in coagulation management, Gregory Hans

Temperature management
11.15 Retrospective local results, Jean-Noël Koch
11.25 Deep hypothermia: the gold standard? John Elefteriades
11.35 Modern temperature management in aortic arch surgery, Maximilian Luehr

Ventilation management
11.45 Retrospective local results, Jean-Noël Koch
11.55 Prophylactic NIV: does it improve patient’s outcome? Alastair Glossop
12.05 An innovative approach of CRF treatment: low flow CO₂ removal, Philippe Morimont
12.15 Discussion / Closing remarks
13.15 Lunch break

ePosters - PARALLEL SESSION (Level 2)
ePosters displayed during the whole congress
Competition presentations on Saturday at 10.30

Jury: Helena Kuivaniemi, Frank Lederle

- Transcriptional (ChIP-Chip) analysis of ELF1, ETS2, RUNX1 and STAT5 in human abdominal aortic aneurysm, Robert Erdman
- Does time to theatre affect outcome in the management of ruptured abdominal aortic aneurysms? Morris Idunn
- Evaluation of the multilayer flow modulator in aneurysm repair using porcine animal models, Patricia Kavanagh Edel
- Changes in thread design of the multilayer flow modulator and the effects on biocompatibility, Patricia Kavanagh Edel
- Endothelization kinetics of multilayer versus single layer Intra-arterial stents, Patricia Kavanagh Edel
- Off label use of Valiant graft for treatment of complete endograft migration with major endoleak, Ibrahim Andraos
- Uptake of FDG detected by positron emission tomography in the abdominal aortic aneurysm is correlated with endoleaks and predicts the adverse outcome of AAA after endovascular aortic repair, Audrey Courtois
- Hemodynamic assessment of endoleak using time-resolved phase contrast magnetic resonance imaging, Mayu Sakata
- Volume growth of abdominal aortic aneurysms is predictable and correlates with increasing biomechanical rupture risk, Moritz Lindquist Liljeqvist
- Simultaneous orthotopic liver transplantation with abdominal aortic aneurysm repair, Sef Davorin
- Long term results after retroperitoneal repair for AAA. Single Center Experience, Elpiniki Tsolaki
- Endovascular treatment of type B aortic dissection with aortic coarctation, Arnaud Kerzmann
- Establishment of a new murine elastase-induced aneurysm model combined with transplantation, Zuzanna Rowinska
- Current morphological limitations of endovascular treatment of infrarenal abdominal aortic aneurysm, Jolanta Tomczak
- Elevating plasma high-density lipoproteins reduce experimental abdominal aortic aneurysm – investigating the therapeutic potential, Christopher Huggins
- Long-term experience of surgery of TAAD type A in Ukraine, Vitalii Kravchenko
- ApoA-1/HDL as diagnostic, prognostic and therapeutic biomarkers of abdominal aortic aneurysm, Monica Torres-Fonseca
Thursday September 11

**Medtronic SIMULATION WORKSHOP**

- **Information on Medtronic booth**
- **TAVI / Corevalve – EVAR / Endurant II**

Friday September 12

**Medtronic SIMULATION WORKSHOP**

- **Information on Medtronic booth**
- **TAVI / Corevalve – EVAR / Endurant II**

11.30 **Medtronic SYMPOSIUM**

- **Auditorium - Salle de bal**
- **Endovascular treatment AAA-TAA**
  - **Moderator:** Eric Verhoeven
  - AAA progression of disease, implications for endovascular treatment,
    Eric Verhoeven, Nürnberg, Germany
  - Aortic arch debranching and thoracic endovascular repair,
    Erik Debing, Brussels, Belgium
  - How far to go? EVAR Case,
    Denis Henroteaux, Liège, Belgium

13.30 **WORKSHOP**

- **Salon Grétry - Level 2**
- **Zenith Alpha Thoracic**

Saturday September 13

14.00 **SORIN GROUP SYMPOSIUM**

- **Auditorium - Salle de bal**
- **Perceval sutureless aortic valve**
  - **Moderator:** Jean-Olivier Defraigne
  - World wide experience and 5 year follow-up,
    Bart Meuris, KUL Leuven
  - Learning curve and pitfalls,
    Laurent de Kerchove, UCL St Luc
  - From selected cases to routine use,
    Jean-Marc Marnette, CHR Namur
  - Perceval sutureless aortic valve through mini-thoracotomy: early experience,
    Filip Rega, KUL Leuven
Meeting venue
Crowne Plaza Hotel
9-11, rue du Mont St Martin, Liège
www.crowneplazaliege.be

HOTELS
1. Crowne Plaza*****
   9-11, rue du Mont St Martin
2. Ibis Liège Centre Opéra***
   41, place de la république Française

REGISTRATION & INFORMATION DESK
Thursday .................. 07.30 - 19.30
Friday .................... 08.00 - 19.00
Saturday .................. 08.00 - 18.00

SOCIAL EVENT
IMAD Official dinner
Friday, September 12, 20.00
Palais Provincial
Meeting point: 19.45 in front of the Crowne Plaza - 5 min. walk.

EXHIBITORS

<table>
<thead>
<tr>
<th>BOOTH</th>
<th>COMPANY</th>
<th>BOOTH</th>
<th>COMPANY</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>SORIN</td>
<td>10</td>
<td>ST JUDE MEDICAL</td>
</tr>
<tr>
<td>2</td>
<td>TOILETS</td>
<td>11</td>
<td>VITALITEC</td>
</tr>
<tr>
<td>3</td>
<td>EUROX</td>
<td>12</td>
<td>MAQUET</td>
</tr>
<tr>
<td>4</td>
<td>EDWARDS</td>
<td>13</td>
<td>COOK MEDICAL</td>
</tr>
<tr>
<td>5</td>
<td>Auditorium</td>
<td></td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>JOTEC</td>
<td>14</td>
<td>MEDTRONIC</td>
</tr>
<tr>
<td>7</td>
<td>TAKEDA</td>
<td>15</td>
<td>HOSPITERA</td>
</tr>
<tr>
<td>8</td>
<td>BOSTON SCIENTIFIC</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

EXHIBITION HOURS
Thursday September 11
07.30 - 19.00
Friday September 12
08.00 - 18.30
Saturday September 13
08.00 - 14.00
IMAD 2014 in Liège, Belgium is compliant with the Eucomed Code of Ethical Business Practice.

Mdeon Visa number: 14/V2/4726/003913.

EVENT COORDINATORS’ CONTACTS

Christine Arzouyan
General organization
Mobile: +33 613 96 08 70
carzouyan@divine-id.com

Michèle Caboste
Registration & accommodation
Mobile: +33 646 10 48 26
mcaboste@divine-id.com

Vérane Bergeron Moreau
Executive manager
Mobile: +33 621 78 87 16
vbergeron@divine-id.com

LOCAL CONTACT

Geneviève Péters
Scientific program
Dept of Cardiovascular & Thoracic Surgery
CHU Liège • 4000 Liège • Belgium
Tel.: + 32 4 366 43 49
genevieve.peters@chu.ulg.ac.be

ORGANIZATION

divine [id] agency
17, rue Venture • 13001 Marseille • France
Tel.: +33 491 57 19 60
Fax: +33 491 57 19 61
info@divine-id.com
www.divine-id.com